Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
TLDR
Improving adherence in schizophrenia may have a considerable positive impact on patients and society by focusing on the identified multitude of factors driving nonadherence, including lack of insight, medication beliefs and substance abuse.Abstract:
Background:Nonadherence to medication is a recognized problem and may be the most challenging aspect of treatment.Methods:We performed a systematic review of factors that influence adherence and the consequences of nonadherence to the patient, healthcare system and society, in patients with schizophrenia. Particular attention was given to the effect of nonadherence on hospitalization rates, as a key driver of increased costs of care. A qualitative systematic literature review was conducted using a broad search strategy using disease and adherence terms. Due to the large number of abstracts identified, article selection was based on studies with larger sample sizes published after 2001. Thirty-seven full papers were included: 15 studies on drivers and 22 on consequences, of which 12 assessed the link between nonadherence and hospitalization.Results:Key drivers of nonadherence included lack of insight, medication beliefs and substance abuse. Key consequences of nonadherence included greater risk of relapse,...read more
Citations
More filters
Journal ArticleDOI
Delphi panel to obtain clinical consensus about using long-acting injectable antipsychotics to treat first-episode and early-phase schizophrenia: Treatment goals and approaches to functional recovery
Celso Arango,Andrea Fagiolini,Philip Gorwood,John M. Kane,S. Diaz-Mendoza,Navdeep Sahota,Christoph U. Correll +6 more
TL;DR: A three-step modified Delphi panel process was used to obtain expert consensus on using LAIs with first-episode psychosis (FEP) and early-phase (EP) schizophrenia patients as discussed by the authors .
Journal ArticleDOI
The Importance of Family Support in Successful Treatment Adherence of Schizophrenic Patient
TL;DR: In this paper, the importance of family support of schizophrenic patient in patient's adherence to achieve a good mental health for all family member is discussed, the patient in this case suffered a relapse of his paranoid schizophrenia because he stopped taking medication.
Posted ContentDOI
Predictors of medication adherence in a large one-year prospective cohort of individuals with schizophrenia: Insights from the Multicentric FACE-SZ Dataset
TL;DR: In this article , a two-step cluster analysis and multivariate logistic regression were conducted to identify medication adherence profiles based on the Medication Adherence rating Scale (MARS) and baseline predictors.
Journal ArticleDOI
P.546 Is self-compassion linked to treatment adherence in schizophrenia?
L. Uzer-Kremers,M.C. Bralet,B. Angerville,J. Jeanblanc,Mickaël Naassila,Olivier Pierrefiche,Alain Dervaux +6 more
Journal ArticleDOI
Microneedle array patches for sustained delivery of fluphenazine: A micron scale approach for the management of schizophrenia.
Lalitkumar K. Vora,Fabiana Volpe-Zanutto,Akmal H. Sabri,Kelly C. Peng,Qonita Kurnia Anjani,Peter E. McKenna,Anastasia Ripolin,Eneko Larraňeta,Helen O. McCarthy,Ryan F. Donnelly +9 more
TL;DR: In this article , three microneedle (MN) systems were developed to deliver fluphenazine (FLU) systemically, which can transport hydrophobic molecules from the skin to the systemic circulation.
References
More filters
Journal ArticleDOI
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: An Explanation and Elaboration of the PRISMA Statement is presented and updated guidelines for the reporting of systematic reviews and meta-analyses are presented.
Journal ArticleDOI
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
Alessandro Liberati,Douglas G. Altman,Jennifer Tetzlaff,Cynthia D. Mulrow,Peter C Gøtzsche,John P. A. Ioannidis,Mike Clarke,Mike Clarke,Philip J. Devereaux,Jos Kleijnen,David Moher +10 more
TL;DR: This Explanation and Elaboration document explains the meaning and rationale for each checklist item and includes an example of good reporting and, where possible, references to relevant empirical studies and methodological literature.
Journal ArticleDOI
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Jeffrey A. Lieberman,T. Scott Stroup,Joseph P. McEvoy,Joseph P. McEvoy,Marvin S. Swartz,Robert A. Rosenheck,Diana O. Perkins,Richard S.E. Keefe,Sonia M. Davis,C.E. Davis,Barry D. Lebowitz,Joanne B. Severe,John K. Hsiao +12 more
TL;DR: Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Journal ArticleDOI
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more
TL;DR: Recommendations for addressing adherence problems to improve patient outcomes are developed, noting that multiple problems may be involved, requiring a combination of interventions.
Journal ArticleDOI
Partial Compliance and Risk of Rehospitalization Among California Medicaid Patients With Schizophrenia
TL;DR: This study showed a direct correlation between estimated partial compliance and hospitalization risk among patients with schizophrenia across a continuum of compliance behavior.
Related Papers (5)
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.
Alan S. Bellack,Charles L. Bowden,Christopher R. Bowie,Matthew J. Byerly,William T. Carpenter,Laurel A. Copeland,Albana M Dassori,John M. Davis,Colin A. Depp,Esperanza Diaz,Lisa B. Dixon,John P. Docherty,Eric B. Elbogen,S. Nasser Ghaemi,Paul E. Keck,Samuel J. Keith,Martijn J. Kikkert,John Lauriello,Barry D. Lebotz,Stephen R. Marder,Joseph P. McEvoy,David J. Miklowitz,Alexander L. Miller,Paul A. Nakonezny,Henry A. Nasrallah,Michael W. Otto,Roy H. Perlis,Delbert G. Robinson,Gary S. Sachs,Martha Sajatovic,Nina R. Schooler,S. Charles Schulz,Jan Scoff,Jair C. Soares,Stephen M. Strakowski,Holly A. Swartz,Marcia Valenstein,Dawn I. Velligan,Peter J. Weiden,Emily M. Woltmann,John E. Zeber +40 more